Filter by brand
Hymovis is a type of orthopaedic injectable indicated for the management of symptoms associated with osteoarthritis of the knee. Patients with this condition suffer from debilitating joint pain and swelling which progresses, potentially leading to a loss of mobility. Hymovis addresses knee pain through viscosupplementation, where the product helps to cushion and reduce friction in the diseased joint to protect against future joint damage. Hymovis is a highly viscous hydrogel made utilizing proprietary technology to enhance its biomechanical characteristics of elasticity and viscosity without using a chemical cross-linking agent. It is engineered to possess the biomechanical properties similar to hyaluronan typically found in healthy synovial fluid, allowing Hymovis to emulate and restore the rheological state of a normal knee joint. Hymovis is clinically proven to remain in the knee joint for a longer duration of time compared to other hyaluronic acid preparations, resulting in more effective and longer-lasting outcomes. With Hymovis, further joint damage can be prevented, and inflammation, swelling, and pain is reduced. Manufactured by the Italian pharmaceutical company Fidia, this product received FDA approval in 2015.
Hymovis injections provide pain relief lasting for up to six months in patients with knee osteoarthritis.
Hymovis injections are considered safe due to the hypoallergenic nature of the product and the minimally invasive administration procedure. Moreover, Hymovis is manufactured without any cross-linking agents and is made from bacterial hyaluronic acid, further enhancing its safety and tolerability profile. That being said, this product is not suitable for patient groups. In particular, Hymovis should not be used in patients who are allergic to hyaluronate-based products or Gram-positive bacterial proteins. Patients with active injection or skin conditions in the planned treatment area or joint also should not receive Hymovis injections. Lastly, patients who are pregnant, breastfeeding, or under 18 years of age should be excluded from Hymovis treatment.
The above information does not constitute all the information about safety and contraindications. Consult a product’s package insert for more information on these matters.
Some of the side effects these products can cause include but are not limited to the following:
The is no recovery time associated with Hymovis injections. The patient is usually able to resume their daily activities after a Hymovis injection.
Hymovis ranges in price from $579.00 to $599.00.